Why is TNBC so difficult to treat?

Triple-negative breast cancer has fewer treatment options than other types of invasive breast cancer. This is because the cancer cells do not have the estrogen or progesterone receptors or enough of the HER2 protein to make hormone therapy or targeted drugs work.

What is molecular classification?

What are the molecular subgroups? The current molecular classification divides breast cancer into five groups as luminal A, luminal B, HER-2, basal and normal breast like. Further grouping of these subgroups seem possible and necessary.

How are breast cancers classified?

Traditional, Old Fashioned Practice. Invasive breast cancer is currently classified as non-specific ductal carcinoma and specific subtypes. Special subtypes of breast cancer have specific definitions, while the non-specific type is like a dumpster containing all carcinomas other than specific subtypes.

Does TNBC respond to chemo?

And although TNBC tends to respond well to initial chemo, it tends to come back (recur) more frequently than other breast cancers.

What is the life expectancy of someone with triple negative breast cancer?

In general, about91\% of all women with triple-negative breast cancer are still alive 5 years after diagnosis. If the cancer has spread to the lymph nodes near the breast (regional) the 5 year relative survival rate is about 65\%. If the cancer has spread to distant places, the 5 year relative survival rate is 11\%.

Why is triple negative breast cancer so hard to treat?

Triple-negative breast cancer is different from the more common types of breast cancer. It is harder to treat and much more aggressive. Because it is aggressive and rare, fewer treatment options are available. It also tends to have a higher rate of recurrence.

What is triple negative breast cancer and how is it treated?

Big Changes Coming in Treatment of Triple-Negative Breast Cancer Refining Chemotherapy for TNBC. In a phase 3 trial, 1 labeled Study 301, Halaven (eribulin mesylate) was compared with the chemotherapy capecitabine in previously treated patients with locally advanced or Novel Strategies in TNBC. Androgen Receptor Signaling.